CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Masahiro, Inoue, Akihiro, Ohnishi, Takanori, Yano, Hajime, Kanemura, Yonehiro, Kohno, Shohei, Ohue, Shiro, Ozaki, Saya, Matsumoto, Shirabe, Suehiro, Satoshi, Nakamura, Yawara, Shigekawa, Seiji, Watanabe, Hideaki, Kitazawa, Riko, Tanaka, Junya, Kunieda, Takeharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957167/
https://www.ncbi.nlm.nih.gov/pubmed/33543833
http://dx.doi.org/10.1002/cam4.3767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957167/
https://www.ncbi.nlm.nih.gov/pubmed/33543833
http://dx.doi.org/10.1002/cam4.3767

Ejemplares similares